GH vs ICLR vs NTRA Stock Comparison

Guardant Health, Icon and Natera Prices as of Nov 13, 2026 Peers: Industry group
GH Guardant Health, Inc.
$151.70 -6.9% 1M +61.2% 1Y
Market cap
$19.46B
P/E
–
Revenue (TTM)
$1.28B
Div. yield
–
Diagnostic Labs Healthcare
2 wins
ICLR Icon Plc
$194.65 +15.2% 1M +19.1% 1Y
Market cap
$15.01B
P/E
33.4x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
4 wins
NTRA Natera, Inc.
$319.09 -19.2% 1M +59.0% 1Y
Market cap
$42.09B
P/E
–
Revenue (TTM)
$2.91B
Div. yield
–
Diagnostic Labs Healthcare
3 wins

Head to Head

9 decided of 12

Icon leads on 4 of the 12 questions below (Icon 4, Natera 3, Guardant Health 2). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionGHICLRNTRALeader
Larger companyMarket capitalisation $19.46B $15.01B $42.09B NTRA
Cheaper on earningsLower P/E, profitable companies only -40.1x 33.4x -255.5x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS — 19.0x — –
Faster revenue growthRevenue growth, trailing twelve months +41.7% +1.8% +37.4% GH
More profitableNet margin, trailing twelve months -37.9% 5.4% -5.7% ICLR
Better return on capitalReturn on invested capital — 4.7% -9.9% ICLR
Less leveragedLower net debt / EBITDA — 2.3x 5.6x ICLR
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +61.2% +19.1% +59.0% GH
Better 5-year returnAnnualised price return, 5 years +7.9%/yr -7.4%/yr +22.7%/yr NTRA
Less volatileAnnualised volatility, 1 year 53.0% 74.9% 52.1% NTRA
Higher overall scoreMean of the five percentile scores vs peers 27/100 78/100 52/100 ICLR

Percentile Scorecard

GHICLRNTRA

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisGHICLRNTRA
Valuation 15 #84 of 99 100 #1 of 11 13 #86 of 99
Growth 44 #50 of 89 50 #6 of 11 80 #19 of 89
Profitability 9 #84 of 92 80 #3 of 11 35 #60 of 92
Financial Health 54 #48 of 103 75 #4 of 13 85 #16 of 103
Shareholder Returns 13 #55 of 63 86 #2 of 8 45 #35 of 63
Overall 27 78 52
  • GH ranked among 103 companies in Healthcare Providers
  • ICLR ranked among 13 companies in Pharma Services
  • NTRA ranked among 103 companies in Healthcare Providers

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodGHICLRNTRASPY
1 month -6.9%+15.2%-19.2% -2.0%
3 months -3.5%+19.3%+3.0% -2.8%
6 months +59.8%+67.3%+71.2% +2.0%
Year to date +48.5%+6.8%+39.3% +10.6%
1 year +61.2%+19.1%+59.0% +12.2%
3 years +519.4%-27.1%+512.2% +68.1%
3 years, per year +83.7%-10.0%+83.0% +18.9%
5 years +46.1%-31.8%+177.4% +61.4%
5 years, per year +7.9%-7.4%+22.7% +10.1%
10 years —+142.7%+2,761.8% +248.5%
10 years, per year —+9.3%+39.9% +13.3%

Risk

MeasureGHICLRNTRASPY
Volatility, 1Y 53.0%74.9%52.1% 13.6%
Downside volatility, 1Y 50.7%87.1%53.1% 13.9%
Beta vs S&P 500, 1Y 1.321.291.29 1.00
Return / volatility, 1Y 1.150.251.13 0.90
Max drawdown, 5Y -85.0%-76.9%-75.7% -25.4%
From 52-week high -19.0%-9.7%-26.8% -3.2%
52-week high $187.22$215.48$436.00 $779.14
52-week low $78.60$80.08$182.65 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleGHICLRNTRA
P/E now vs peer median -42.0xmedian 22.4x 34.0xmedian 34.7x -279.0xmedian 22.4x
P/S now vs peer median 16.0xmedian 1.3x 1.8xmedian 2.5x 15.8xmedian 1.3x
EV/EBITDA now vs peer median -40.6xmedian 14.2x 16.0xmedian 29.1x -248.1xmedian 14.2x
P/FCF now vs peer median -88.0xmedian 19.0x 17.4xmedian 21.0x 877.9xmedian 19.0x
P/B now vs peer median -74.1xmedian 2.6x 1.6xmedian 1.6x 24.6xmedian 2.6x
PEG now vs peer median -72.47median 0.84 -11.35median 1.98 -7.78median 0.84

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsGHICLRNTRA
Revenue $1.28B $8.23B $2.91B
Gross profit $833.70M $1.93B $1.84B
Operating income -$504.04M $718.25M -$260.42M
Net income -$485.07M $448.66M -$164.72M
Free cash flow -$232.15M $857.06M $52.47M
R&D $386.67M – $856.40M
EPS (diluted) $-3.61 $5.68 $-1.14
Cash & equivalents $1.03B $808.98M $1.10B
Total debt – $3.38B $80.30M
Shares (diluted) 134.42M 78.97M 144.07M
Enterprise value $15.08B $11.78B $37.72B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricGHICLRNTRA
P/E -42.0x 34.0x -279.0x
P/FCF -88.0x 17.4x 877.9x
P/Operating cash flow -117.8x 14.5x 216.5x
P/S 16.0x 1.8x 15.8x
P/B -74.1x 1.6x 24.6x
P/Tangible book -67.9x 2.5x 30.4x
EV/EBITDA -40.6x 16.0x -248.1x
EV/EBIT -38.5x 24.3x -173.0x
EV/Revenue 15.2x 2.1x 15.5x
EV/FCF -83.6x 20.4x 858.4x
EV/Operating cash flow -111.9x 17.0x 211.7x
PEG (3Y EPS CAGR) -72.47 -11.35 -7.78

Growth

14 metrics
MetricGHICLRNTRA
Revenue growth (1Y) 41.7% 1.8% 37.4%
Revenue CAGR (3Y) 33.6% 0.9% 43.3%
Gross profit growth (1Y) 44.9% -13.4% 41.1%
Gross profit CAGR (3Y) – -6.5% 68.2%
Operating income growth (1Y) -13.9% 53.9% 26.0%
Operating income CAGR (3Y) 0.6% -7.0% 19.7%
Net income growth (1Y) -21.6% 55.9% 46.7%
Net income CAGR (3Y) -3.9% -4.4% 30.9%
EPS growth (1Y) -12.9% 30.1% 49.3%
EPS CAGR (3Y) 0.6% -3.0% 35.9%
Operating cash flow growth (1Y) 22.2% -9.9% 9.5%
Operating cash flow CAGR (3Y) 19.9% 15.8% 40.7%
Free cash flow growth (1Y) 11.5% -11.1% -50.5%
Free cash flow CAGR (3Y) 13.9% 18.4% 29.4%

Profitability

14 metrics
MetricGHICLRNTRA
Gross margin 65.2% 23.4% 63.3%
EBITDA margin -37.4% 13.3% -6.2%
Operating margin -39.4% 8.7% -9.0%
Pretax margin -38.0% 6.3% -7.7%
Net margin -37.9% 5.4% -5.7%
FCF margin -18.2% 10.4% 1.8%
Operating cash flow margin -13.6% 12.5% 7.3%
Return on equity – 7.6% -8.9%
Return on assets -25.5% 4.3% -6.1%
Return on invested capital – 4.7% -9.9%
Return on capital employed -33.0% 5.3% -12.5%
Asset turnover 0.7x 0.5x 1.1x
Cash conversion (OCF / net income) 0.4x 2.3x -1.3x
Stock comp / revenue 16.5% 1.1% 13.6%

Financial Health

11 metrics
MetricGHICLRNTRA
Debt / assets – 20.8% 2.9%
Debt / equity – 0.4x 0.0x
Net debt / EBITDA – 2.3x 5.6x
Debt / FCF – 3.9x 1.5x
Liabilities / assets 114.6% 43.8% 32.0%
Equity / assets -14.6% 56.2% 68.0%
Interest coverage -96.6x 3.4x -70.8x
Current ratio 3.6x 1.3x 2.8x
Quick ratio 3.3x 0.9x 2.6x
Cash ratio 2.8x 0.3x 1.8x
Altman Z-score 3.60 2.15 31.15

Shareholder Returns

7 metrics
MetricGHICLRNTRA
Dividend yield – – –
Net buyback yield -2.0% 2.6% -0.1%
Shareholder yield -2.0% 2.6% -0.1%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusGHICLRNTRA
Forward P/E – 19.0xFY2026 –
EPS, next fiscal year $-3.46FY2026 $10.26FY2026 $-1.62FY2026
EPS growth, next FY – -18.1%FY2026 –
EPS growth, the year after – +20.1% –
Revenue, next fiscal year $1.43BFY2026 $8.54BFY2026 $3.16BFY2026
Revenue growth, next FY +45.5%FY2026 +3.5%FY2026 +36.9%FY2026
Revenue growth, the year after +26.0% -2.2% +7.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersGHICLRNTRA
Held by institutions 100.0% 100.0% 95.5%
Institutions holding 597 424 850
Change in shares held, QoQ -2.5% +5.5% +2.7%
Institutions buying 356 233 515
Institutions selling 180 139 240
Buyers to sellers 1.98 1.68 2.15

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

GHICLRNTRA
GH 1.00 0.25 0.60
ICLR 0.25 1.00 0.23
NTRA 0.60 0.23 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, GH, ICLR and NTRA?

Natera (NTRA) is the largest by market capitalisation: Guardant Health (GH) $19.46B, Icon (ICLR) $15.01B, Natera (NTRA) $42.09B.

Which company is growing faster?

Guardant Health (GH) grew revenue fastest over the trailing twelve months: Guardant Health (GH) +41.7%, Icon (ICLR) +1.8%, Natera (NTRA) +37.4%.

Which company is more profitable?

Icon (ICLR) has the highest net margin (Guardant Health (GH) -37.9%, Icon (ICLR) 5.4%, Natera (NTRA) -5.7%). On return on invested capital, Icon (ICLR) leads (Icon (ICLR) 4.7%, Natera (NTRA) -9.9%).

Which stock has performed better?

Over the past year Guardant Health (GH) returned the most: Guardant Health (GH) +61.2%, Icon (ICLR) +19.1%, Natera (NTRA) +59.0%. Over five years, Natera (NTRA) compounded fastest (Guardant Health (GH) +7.9%/yr, Icon (ICLR) -7.4%/yr, Natera (NTRA) +22.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Natera (NTRA) has been the steadiest (Guardant Health (GH) 53.0%, Icon (ICLR) 74.9%, Natera (NTRA) 52.1%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, GH, ICLR and NTRA?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Icon (ICLR) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.